US biotech Biogen (Nasdaq: BIIB) has taken a chance on one of the assets that Pfizer (NYSE: PFE) is keen to offload after the pharma giant announced that it was shutting down its R&D in neurosciences.
The deal is for PF-04958242, a Phase IIb-ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia, and includes an upfront payment of $75 million with up to $515 million in additional development and commercialization milestone payments, as well as tiered royalties in the low to mid-teen percentages.
Biogen will not waste any time, starting a Phase IIb trial of this newly-acquired asset in the second half of 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze